Malignant Peritoneal and Retroperitoneal Neoplasm

Malignant Peritoneal and Retroperitoneal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

631 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 163
Recruiting: 76
Ph III recruiting: 8
Growth YoY: −39.1%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (92)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07743164	A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)	not yet recruiting	Phase 3	646	Merck Sharp & Dohme LLCINDUSTRY	0	Sep 11, 2026	clinicaltrials
NCT06867562	Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer	not yet recruiting	Phase 3	166	Jina Pharmaceuticals Inc.INDUSTRY